Xencor, Inc Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31)
Xencor, Inc (XNCR) reported Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) of -$367.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 · last filed 2018-02-28
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-12-31 was -$711.00K.
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $143.00K.
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-06-30 was -$44.00K, a 138.94% decline year-over-year.
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $245.00K, a 60.42% decline year-over-year.
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2017 was -$367.00K.
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2016 was -$925.00K.
- Xencor, Inc available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2015 was -$516.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 3 month as first filed | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 6 month as first filed | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 9 month as first filed | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$711.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$568.00K derived: sum of 2 quarters · filed 2018-02-28 | -$612.00K derived: sum of 3 quarters · filed 2018-02-28 | -$367.00K 10-K · filed 2018-02-28 | |||
| 2017-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $99.00K derived: sum of 2 quarters · filed 2017-11-08 | $344.00K 10-Q · filed 2017-11-08 | -$847.00K derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2017-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $201.00K 10-Q · filed 2017-08-07 | -$990.00K derived: sum of 3 quarters · filed 2018-02-28 | -$1.46M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2017-03-31 | $245.00K 10-Q · filed 2017-05-10 | -$946.00K derived: sum of 2 quarters · filed 2018-02-28 | -$1.41M derived: sum of 3 quarters · filed 2018-02-28 | -$1.30M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$1.66M derived: sum of 2 quarters · filed 2018-02-28 | -$1.54M derived: sum of 3 quarters · filed 2018-02-28 | -$925.00K 10-K · filed 2018-02-28 | |||
| 2016-09-30 | -$466.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$353.00K derived: sum of 2 quarters · filed 2017-11-08 | $266.00K 10-Q · filed 2017-11-08 | -$266.00K 10-Q · filed 2016-11-02 | -$244.00K derived: sum of 4 quarters · filed 2018-02-28 | ||
| 2016-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $732.00K 10-Q · filed 2017-08-07 | -$732.00K 10-Q · filed 2016-08-03 | $222.00K derived: sum of 3 quarters · filed 2018-02-28 | $126.00K derived: sum of 4 quarters · filed 2018-02-28 | ||
| 2016-03-31 | $619.00K 10-Q · filed 2017-05-10 | -$619.00K 10-Q · filed 2016-05-02 | $109.00K derived: sum of 2 quarters · filed 2018-02-28 | $13.00K derived: sum of 3 quarters · filed 2018-02-28 | $68.00K derived: sum of 4 quarters · filed 2018-02-28 | ||
| 2015-12-31 | -$510.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$606.00K derived: sum of 2 quarters · filed 2018-02-28 | -$551.00K derived: sum of 3 quarters · filed 2018-02-28 | -$516.00K 10-K · filed 2018-02-28 | |||
| 2015-09-30 | -$96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$41.00K derived: sum of 2 quarters · filed 2016-11-02 | -$6.00K 10-Q · filed 2016-11-02 | ||||
| 2015-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $90.00K 10-Q · filed 2016-08-03 | -$90.00K 10-Q · filed 2015-08-05 | ||||
| 2015-03-31 | $35.00K 10-Q · filed 2016-05-02 | -$35.00K 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |